We deliver

Inspired clinical

development solutions

across the drug development life cycle

Our services:

Science & Strategy

  • Scientific strategy

  • Clinical development

  • Regulatory expertise

  • Scientific advisory boards

Clinical Excellence

  • Clinical trial feasibility

  • Oversight of clinical studies

  • Choosing the right CRO

  • Quality management systems

Strategy & Transformation

  • Transformation

  • Growth

  • Due diligence

  • Company creation

Our impact

“We see Weatherden playing an increasingly important role in the global biotechnology sector. Our input is rapidly scaling across all segments and we are excited to see this translate into tangible improvements in patient outcomes and value realisation for our clients.”

a 70c-.png

>200 companies

We have advised, worked with and supported dozens of funds and biotechs.

b 200m-.png

>500 million plus

Our input is benefitting patient populations worldwide.

c 13b-.png

>25 billion USD

Our repeat and long-term clients have realised significant value gains since we became involved in their programmes.

 

Founded by world leading clinicians

“In just three years we disrupted the market, attracting dozens of international clients drawn by our 360-degree vision of drug development, exceptional portfolio of in-house expertise and network of leading external experts. We even succeeded in keeping clinical trials running during Covid-19's crisis point.”

  • Professor Houman Ashrafian

    CO-FOUNDER & CHAIRMAN

    Professor Ashrafian is a clinician scientist, serial entrepreneur, investor and company builder. He has received dozens of awards and authored over 70 publications.

  • Dr Duncan McHale

    CO-FOUNDER

    Duncan is a clinical geneticist and early drug development expert. He has over 30 years of industry experience, sits on multiple MRC panels and authored the ICH E15 and E16 guidelines.

  • Emma Tinsley

    CHIEF EXECUTIVE

    Emma is a nationally recognised serial entrepreneur who has built multiple companies with breakthrough therapies and is bringing to market deep tech solutions that will transform clinical trial design efficiency.

Our track record

 

Client
satisfaction

a Client sat.png

An above average rate of repeat business and word-of-mouth driven new client relationships reflects the quality of our input and the outcomes we achieve​.

Clinical
successes

b Clin successes.png

With a track record of successful clinical trials in multiple cities and countries, our thoughtful design and integrated approach can chart your fastest path to efficacy in patients.

900+ years’
experience

Blending more than 900 years’ experience, we are uniquely positioned to de-risk your programs and maximise value across the drug development lifecycle.

International
reach

d Intl reach.png

We can manage single and multi-centre trials across the world – our current portfolio involves 15 cities across 12 countries, including Brazil, France, New Zealand, Spain, the UK and USA.

Regulatory
wins

e Regulatory win.png

We have led multiple defence meetings with regulatory authorities, including the MHRA, FDA, EMA (including CHMP, SAG, COMP and PDCO), MEB, AEMPS, BfArM, and PEI.

Therapeutic
areas

f Therapeutic areas.png

Our expertise spans more than 30 therapeutic areas, which is augmented further by our network of KOLs.

Latest news